US FDA approves Novartis’ gene therapy for rare muscle disorder
The U.S. Food and Drug Administration has approved Novartis’ gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday. The therapy, branded as Itvisma, was approved…
